Biogen Inc. (BIIB)
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Healthcare Stocks Have Popped. Consider These 2 That Haven't.
Money has poured into the sector as markets have grown concerned about the economy.
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to treatment due to the new and complicated system associated with taking the drug.
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley's 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone.
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is generating positive longer-term clinical data. Biogen's pipeline includes potential revenue contributors in Alzheimer's, Parkinson's, and kidney disease therapies, pain therapeutics and MS.
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
